[ad_1]
Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.
[ad_2]
Source link
Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.
Published on:
